{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T02:08:10Z","timestamp":1774577290344,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cjcopen.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CJC Open"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.cjco.2024.03.006","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T08:55:23Z","timestamp":1710492923000},"page":"811-817","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Does Disopyramide Still Have a Place in the Management of Obstructive Hypertrophic Cardiomyopathy?"],"prefix":"10.1016","volume":"6","author":[{"given":"St\u00e9phanie","family":"Corriveau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bobak","family":"Heydari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Garceau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjco.2024.03.006_bib1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","article-title":"Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults","volume":"92","author":"Maron","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2024.03.006_bib2","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2024.03.006_bib3","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"76","author":"Ommen","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2024.03.006_bib4","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2024.03.006_bib5","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2024.03.006_bib6","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.cjco.2024.03.006_bib7","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2024.03.006_bib8","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/europace\/eum093","article-title":"Syncope in hypertrophic cardiomyopathy: mechanisms and consequences for treatment","volume":"9","author":"Williams","year":"2007","journal-title":"Europace"},{"key":"10.1016\/j.cjco.2024.03.006_bib9","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/eurheartj\/ehs150","article-title":"Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence","volume":"33","author":"Spoladore","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2024.03.006_bib10","article-title":"Safety of outpatient initiation of disopyramide for obstructive hypertrophic cardiomyopathy patients","volume":"6","author":"Adler","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjco.2024.03.006_bib11","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies: developed by the Task Force on the Management of Cardiomyopathies of the European Society of Cardiology (ESC)","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2024.03.006_bib12","first-page":"2725","article-title":"Real-world use and predictors of response to disopyramide in patients with obstructive hypertrophic cardiomyopathy","volume":"12","author":"Maurizi","year":"2023","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.cjco.2024.03.006_bib13","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2165\/00002018-200023060-00003","article-title":"Antiarrhythmic agents: drug interactions of clinical significance","volume":"23","author":"Trujillo","year":"2000","journal-title":"Drug Saf"},{"key":"10.1016\/j.cjco.2024.03.006_bib14","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Sherrid","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2024.03.006_bib18","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJM198210143071607","article-title":"Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide","volume":"307","author":"Pollick","year":"1982","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2024.03.006_bib19","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/0002-9149(88)90269-X","article-title":"Disopyramide in hypertrophic cardiomyopathy. II. Noninvasive assessment after oral administration","volume":"62","author":"Pollick","year":"1988","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjco.2024.03.006_bib20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1536\/ihj.29.115","article-title":"Danger of use of disopyramide in patients with hypertrophic obstructive cardiomyopathy. An electrophysiologic study","volume":"29","author":"Miyajima","year":"1988","journal-title":"Jpn Heart J"},{"key":"10.1016\/j.cjco.2024.03.006_bib21","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/CIRCHEARTFAILURE.112.000122","article-title":"Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with \u03b2-blockade or verapamil","volume":"6","author":"Sherrid","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjco.2024.03.006_bib22","first-page":"7325","article-title":"Impact of short-acting disopyramide on left ventricular mechanics evaluated by strain analysis in patients with hypertrophic obstructive cardiomyopathy","volume":"11","author":"Yedidya","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.cjco.2024.03.006_bib23","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","article-title":"Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Dybro","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2024.03.006_bib24","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cjco.2024.03.006_bib25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2024.03.006_bib26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["CJC Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X24001380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X24001380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T23:14:58Z","timestamp":1720134898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589790X24001380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2589790X24001380"],"URL":"https:\/\/doi.org\/10.1016\/j.cjco.2024.03.006","relation":{},"ISSN":["2589-790X"],"issn-type":[{"value":"2589-790X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does Disopyramide Still Have a Place in the Management of Obstructive Hypertrophic Cardiomyopathy?","name":"articletitle","label":"Article Title"},{"value":"CJC Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjco.2024.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}